Business Context and Reporting Period
Corbus Pharmaceuticals Holdings, Inc. filed its Form 10-K for the fiscal year ended December 31, 2021; the filing is annual rather than a standalone fourth-quarter report. Corbus is a clinical-stage biopharmaceutical company developing immune modulators for immuno-oncology, fibrosis, inflammation and metabolic disease. Its pipeline includes CRB-601 and CRB-602 anti-integrin monoclonal antibodies, preclinical CB1 inverse agonists, and lenabasum.
- CRB-601 targets solid tumors and is planned for an FDA IND submission in the first half of 2023.
- CRB-602 is a discovery-stage anti-integrin antibody program for oncology and fibrosis.
- The CB1 inverse agonist program remains preclinical.
- Lenabasum’s Phase 3 dermatomyositis study failed to meet its primary endpoint in June 2021. Corbus does not plan additional company-sponsored lenabasum trials and intends to seek licensing partners.
Financial Results and Key Metrics
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Revenue from awards | $0.9 million | $3.9 million | Down $3.1 million |
| Research and development expense | $36.4 million | $98.3 million | Down $61.8 million |
| General and administrative expense | $20.4 million | $28.5 million | Down $8.1 million |
| Total operating expenses | $56.9 million | $126.7 million | Down $69.9 million |
| Operating loss | $56.0 million | $122.8 million | Improved $66.8 million |
| Other income, net | $10.3 million | $11.5 million | Down $1.2 million |
| Net loss | $45.6 million | $111.3 million | Improved $65.6 million |
| Net loss per share | $0.37 | $1.42 | Improved |
| Net cash used in operations | $48.2 million | $99.7 million | Improved $51.5 million |
The company has generated no product-sales revenue and remains unprofitable. Reported 2021 revenue consisted entirely of recognition of the Cystic Fibrosis Foundation award; the related development services were completed by December 31, 2021, and no further revenue is expected from that award. Other income included approximately $12.8 million of refundable foreign research and development tax credits, partly offset by interest expense and foreign-exchange losses.
- Cash and cash equivalents were $25.0 million at year-end, and investments were $72.6 million.
- Total cash, cash equivalents and restricted cash were $25.7 million, while management separately cited approximately $97.6 million of cash, cash equivalents and investments and approximately $98.3 million including restricted cash.
- Working capital was approximately $83.2 million, based on current assets of $100.2 million and current liabilities of $17.0 million.
- Outstanding K2 debt had $20.0 million of stated principal and approximately $21.2 million of total principal obligations including the final payment. The debt matures August 1, 2024 and bears interest at 8.5% at year-end.
- Debt and lease liabilities totaled approximately $24.7 million excluding other liabilities. The K2 facility is secured by substantially all company assets other than intellectual property and includes financial and operating covenants.
- Operating lease payments totaled approximately $8.6 million through 2026, partially offset by $1.1 million of expected sublease inflows.
Material Changes Versus the Prior Comparable Period
- Research and development spending declined primarily because lenabasum clinical studies were completed or winding down, including approximately $31.9 million of lower clinical expenses.
- General and administrative expense declined due to lower compensation, commercial marketing, consulting and recruiting costs.
- Cash used in operations fell by approximately 52%, reflecting reduced development activity and lower operating expenses.
- Investing cash outflows increased to $73.4 million, primarily because the company purchased marketable investments.
- Financing cash inflows declined to $60.8 million from $154.9 million in 2020. The company raised approximately $60.7 million gross through its at-the-market offering in 2021 and issued 25.4 million shares under that program.
- Shares outstanding increased to 125.2 million at December 31, 2021 from 98.9 million at December 31, 2020, creating material dilution for existing holders.
- In May 2021, Corbus entered license agreements for CRB-602 and CRB-601. The agreements involved upfront payments and equity issuance and provide for potential milestone payments of up to $53.0 million to Milky Way and $153.0 million to UCSF, plus royalties.
Guidance, Outlook, Risks and Unusual Items
- Management expects expenses to decline in 2022 because lenabasum studies have ended and the company reduced personnel, but expects continued substantial operating losses.
- Management stated that available cash, cash equivalents and investments should fund operations into the first quarter of 2024 based on planned expenditures. The notes state that liquidity is expected to cover at least 12 months from filing, but additional financing will be required to continue development.
- Corbus expects topline results from the NIH-sponsored Phase 2 systemic lupus erythematosus study of lenabasum in the first half of 2022, with the MD&A referring to data by the end of March 2022.
- On January 3, 2022, Nasdaq notified Corbus that its closing bid price had been below $1.00 for 30 consecutive business days. The company had until July 5, 2022, subject to possible extension and other conditions, to regain compliance or face potential delisting proceedings.
- Venn Therapeutics filed litigation alleging trade-secret misappropriation, breach of contract and related claims concerning CRB-601. Venn also sought a preliminary injunction that could restrict further CRB-601 development. Corbus moved to dismiss and stated that it intends to defend the claims; the outcome is uncertain.
- The company relies on third-party contract manufacturers and clinical research organizations, including a single contract supplier for monoclonal antibodies, creating supply, quality, timing and scalability risks.
- Principal risks include recurring losses, dependence on additional capital, clinical and regulatory failure, intellectual-property disputes, COVID-19-related disruption, dilution, Nasdaq delisting, debt covenants and dependence on licensing or collaboration partners.
- Management reported effective disclosure controls and effective internal control over financial reporting as of December 31, 2021. The independent auditor issued an unqualified opinion on the financial statements but did not audit internal control effectiveness.
Important Facts for Investors to Verify
- Reconcile the reported liquidity figures: $97.6 million of cash, cash equivalents and investments versus approximately $98.3 million including restricted cash, and compare these amounts with the $25.0 million cash balance and $72.6 million investments on the balance sheet.
- Track CRB-601’s preclinical progress, manufacturing scale-up, litigation exposure and planned first-half 2023 IND submission.
- Review the NIH lenabasum systemic lupus erythematosus data and determine whether any licensing partner emerges after the dermatomyositis failure.
- Monitor cash burn, financing capacity, the baby-shelf limitation of approximately $23.9 million while public float remains below $75 million, and the timing of future capital raises.
- Assess K2 debt repayment requirements, covenant compliance and the August 2024 maturity.
- Follow the Venn litigation and any injunction or settlement that could affect CRB-601 development.
- Monitor Nasdaq minimum-bid compliance and any delisting appeal or transfer to the Nasdaq Capital Market.